Floatz logo

CEP-37250

Adenocarcinoma of the Colorectal

Kyowa Kirin Co., Ltd.Phase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

67 Active assets in the Adenocarcinoma of the Colorectal cohort.

Asset / SponsorPhaseRating
Regorafenib
City of Hope Medical Center
Phase 2BB
Trifluridine
Centre Hospitalier Universitaire Dijon
Phase 3BB
Balstilimab
City of Hope Medical Center
Phase 2BB
Botensilimab
City of Hope Medical Center
Phase 2BB
TIPIRACIL
Academic and Community Cancer Research United
Phase 2BB

View all 50 →

Same molecule, other indications

CEP-37250 is also rated in:

pancreatic adenocarcinomaDormant
CC
Indicative ·
47 / 100
View asset →
Solid TumourDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →